Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 52

Results For "SPE"

4967 News Found

$7 million grant to UW Institute for protein design to fuel next-gen enzyme breakthroughs
R&D | March 23, 2026

$7 million grant to UW Institute for protein design to fuel next-gen enzyme breakthroughs

The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington


AptarGroup nasal spray tech joins ENA respiratory’s Phase II trial of INNA?051
Clinical Trials | March 23, 2026

AptarGroup nasal spray tech joins ENA respiratory’s Phase II trial of INNA?051

The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention


Aesthetic Revolution: Global study reveals patients demand personalised, long-term beauty plans
News | March 21, 2026

Aesthetic Revolution: Global study reveals patients demand personalised, long-term beauty plans

The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,


Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare
News | March 21, 2026

Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare

KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval


Pfizer warns shareholders against Tutanota’s mini-tender offer
News | March 21, 2026

Pfizer warns shareholders against Tutanota’s mini-tender offer

Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer


Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer
Clinical Trials | March 21, 2026

Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer

The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival


Touchlight & NEB launch game-changing benchtop DNA kit
News | March 20, 2026

Touchlight & NEB launch game-changing benchtop DNA kit

This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development


Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech
R&D | March 20, 2026

Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech

The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology


NIPER Raebareli–Roche tie-up signals big push for India’s pharma innovation future
R&D | March 20, 2026

NIPER Raebareli–Roche tie-up signals big push for India’s pharma innovation future

The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice